Abstract
Chronic myelogenous leukemia (CML) has a high proportion in hematologic malignancy. Past decade, the appearance and development of tyrosine kinase inhibitors (TKIs) is the milestone of the treatment of CML. TKIs have antitumor effect with inhibition of the phosphorylation of kinases and the downstream signal transduction. In recent years, many large medical institutions at home and abroad worked on clinical experiment researches to investigate the mechanism of TKIs and how to choose TKIs in CML patients. This work is of great significance to the clinic. Key words: Protein-tyrosine kinases/AI/TU; Leukemia, myelogenous, chronic, BCR-ABL positive/DT; Review
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
